Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
2024 · Annals of the Rheumatic Diseases · 51 citations
https://doi.org/10.1136/ard-2023-225445